课题基金 / 基金详情

DEVELOPING A SAFE, NUTRITIONAL SUPPLEMENT FOR CHILDREN WITH DRY SKIN & ECZEMA

DEVELOPING A SAFE, NUTRITIONAL SUPPLEMENT FOR CHILDREN WITH DRY SKIN & ECZEMA
为干性皮肤儿童开发安全、营养的补充剂
批准号:
102942
负责人:
金额:
$23.5万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
Curapel®是一家皮肤保健公司,正在开发专利产品,以帮助人们与常见的,慢性和痛苦的皮肤状况,如湿疹和牛皮癣。Curapel的所有产品都含有经曼彻斯特大学研究人员鉴定的天然安全活性成分。Curapel的理念很简单,我们打算开发基于这些技术的成功产品,这些技术有效地与皮肤生物学一起工作,以“安全治愈皮肤”。湿疹是最常见的皮肤疾病之一,在1-5岁的幼儿中(约20%)的发病率是成人(约3%)的6倍。不幸的是,目前针对这种令人痛苦的状况的产品要么只是舒缓皮肤(润肤剂),要么是具有极其严重副作用的药物,特别是当患有慢性皮肤病的幼儿使用时,Curapel现在正在开发HISTIMEX作为一种安全,易于使用,每天一次的口服营养补充剂,为恢复整个身体的健康皮肤屏障提供重要的构建块。HISTIMEX已在成人中进行了测试,其效果与中等强度的类固醇霜相似,但没有任何副作用。Curapel现在要求Innovate UK帮助资助一种新的儿童友好版HISTIMEX在1-5岁湿疹儿童的临床研究中进行测试。当我们展示了这种新的儿童HISTIMEX的有效性时,我们的目标是在2017年推出它,作为一种安全的产品,适合年轻的湿疹患者。
英文摘要
Curapel® is a skin healthcare company that is developing patented products to help people with common, chronic and distressing skin conditions such as eczema and psoriasis. All Curapel's products contain natural and safe active ingredients which were identified by researchers at the the University of Manchester. The Curapel Philosophy is simple, we intend to develop successful products based on these technologies that work effectively with skin biology to 'Heal Skin Safely'. Eczema is one of the most common skin conditions that is six times more common in young children aged 1-5 years (~20%) than in adults (~3%). Unfortunately, current products for this distressing condition either just soothe the skin (emollients) or are medicines such as steroid creams that have extremely harsh side effects, especially when used by young children suffering from a chronic skin condition Curapel is now developing HISTIMEX as a safe, easy to use, once a day, oral nutritional supplement that provides a vital building block to restore a healthy skin barrier across the whole body. HISTIMEX has been tested in adults and has a similar effect as a middle-strength steroid cream but without any of the side effects. Curapel is now asking Innovate UK to help fund the testing of a new young child-friendly version of HISTIMEX in a clinical study in 1-5 year old children with eczema. When we have shown the effectiveness of this new children's HISTIMEX, we aim to launch it in 2017 as a safe product for young eczema sufferers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
叶绿体蛋白SAFE1和SAFE2介导单线态氧信号转导的机理研究
  • 批准号:
    32170284
  • 项目类别:
    面上项目
  • 资助金额:
    60万元
  • 批准年份:
    2021
  • 负责人:
    王良省
  • 依托单位:
基于Safe screening的多任务稀疏学习理论与算法的研究
  • 批准号:
    12071475
  • 项目类别:
    面上项目
  • 资助金额:
    51.0万元
  • 批准年份:
    2020
  • 负责人:
    徐义田
  • 依托单位:
醛糖还原酶(AR)激活SAFE(JAKs/STATs)通路在抵抗下颌下腺缺血再灌注损伤中的作用
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2019
  • 负责人:
    张思恩
  • 依托单位:
基于Safe screening 的支持向量机的稀疏理论及其快速求解方法
  • 批准号:
    11671010
  • 项目类别:
    面上项目
  • 资助金额:
    48.0万元
  • 批准年份:
    2016
  • 负责人:
    徐义田
  • 依托单位: